gastro-meet-2018-scientifictracks-abstracts

7 / 24

Page 32
Notes:
conferenceseries.com
Volume 8 Journal of Gastrointestinal & Digestive System Gastro Meet 2018
August 06-07, 2018
August 06-07, 2018 Abu Dhabi, UAE
Gastroenterology and Digestive
Disorders
16th International Conference on
Our method experience and effectiveness using Argon Plasma Coagulator (APC) as a therapy for
Gastroesophageal Reflux Disease (GERD)
Julio Murra-Saca
Hospital Centro de Emergencias San Salvador, El Salvador
Avariety of endoscopic modalities have been introduced to treat GERD, including radiofrequency energy, suturing, plication
and injection therapy. Argon Plasma Coagulation (APC) of the lower esophageal sphincter and gastroesophageal junction
represent a new endoscopic therapy for GERD and has been developed by us with performing and observing during almost
15 years. APC is a diathermy based non-contact therapeutic endoscopic modality that may have a lower risk of perforation
than other tissue ablation techniques. Our work initiated after observing the improvements of symptoms of GERD in a
patient who has suffered for more than 30 years from this disease and also has Barrett esophagus of the long segment in who
we performed in two occasions with one month intervals aggressive ablation therapy with APC. After two therapies with
APC the patient reported that he has abandoned his treatment with PPI because his symptoms disappeared. After having
observed this phenomenon we initiated our protocol of a new therapeutic treatment with APC with deliberated energy from
the gastroesophageal junction in circular motion ascending approximately 6 centimeters. Various rings of ablative therapy are
formed with APC. This is similar mechanism of the Stretta device that it is speculated that RF energy induces coagulation of
the LES and neuronal tissues within the gastroesophageal junction with use of the Stretta device. This procedure also has been
demonstrated to be feasible, as well as safe, and is approved by the FDA for treatment of GERD. Setting: Single endoscopy
center; study period from October 2003 to June 2018. Our purpose was to assess the long-term safety and effectiveness. The
results are as follows: APC Ablation of de Lower third of the esophagus procedure significantly improves GERD symptoms,
quality of life and esophageal acid exposure and eliminates the need for antisecretory medication in the majority of patients
at 12 months. Most patients have manifested the reduction of the symptoms in 70-90% of the cases and 70%-80% showed
heartburn symptom resolution at 3 and 6 months, respectively. Regurgitation symptoms improved 70%-90% at three months.
It can be conclusions that the ablative therapy with argon plasma coagulator for gastroesophageal reflux is safe and effective
and is associated with symptom reductions in patients with GERD.
Biography
Julio Murra-Saca is the Chief of Gastroenterology at Hospital Centro de Emergencias San Salvador, El Salvador working in private practice in a gastrointestinal
endoscopy unit performing diagnostic and therapeutic endoscopy. One of his main skills is the management of gastrointestinal bleeding as well as endoscopic
resection of giant polyps of the colon. He has great experience in the therapeutic use of argon plasma coagulation in the management of multiple conditions in
gastrointestinal endoscopy. He also performs intra-gastric balloons for obesity with 13 years of experience in this area.
Julio Murra-Saca, J Gastrointest Dig Syst 2018, Volume 8
DOI: 10.4172/2161-069X-C3-070